Literature DB >> 15328095

Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.

Darrin J Bast1, M Yue, X Chen, D Bell, L Dresser, R Saskin, L A Mandell, D E Low, Joyce C S de Azavedo.   

Abstract

Surface temperature measured by an infrared temperature-scanning thermometer was used to evaluate disease severity and predict imminent death in a murine model of pneumococcal pneumonia. We showed that a decrease in temperature was associated with increasing severity of disease and concomitant histological changes and also that a temperature of 30 degrees C or less was a predictor of death. Furthermore, viable bacterial counts in the lungs of mice euthanized at a temperature of < or = 30 degrees C were not significantly different from those seen in the lungs of mice allowed to die without intervention. These data support temperature change as a more subtle indicator of outcome than death and demonstrate that this could be used as a reliable end point for euthanasia. To test the utility of our model in a drug trial, we examined the efficacies of moxifloxacin and levofloxacin by using temperature as a measure of disease severity prior to and during treatment. Regardless of the antibiotic used, mice assessed as moderately ill (temperature > or = 32 degrees C) at the start of treatment had better clinical and bacteriological outcomes than mice assessed as severely ill (temperature < 32 degrees C). However, moxifloxacin offered better protection and greater bacterial clearance than did levofloxacin in all infected mice independent of disease severity. This model not only allows a more subtle evaluation of drug efficacy but also ensures a better degree of standardization and a more humane approach to drug efficacy studies involving animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328095      PMCID: PMC514736          DOI: 10.1128/AAC.48.9.3343-3348.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Humane endpoints for infectious disease animal models.

Authors:  E D Olfert; D L Godson
Journal:  ILAR J       Date:  2000

2.  The HID50 (hypothermia-inducing dose 50): an alternative to the LD50 for measurement of bacterial virulence.

Authors:  J S Soothill; D B Morton; A Ahmad
Journal:  Int J Exp Pathol       Date:  1992-02       Impact factor: 1.925

3.  The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.

Authors:  P G Ambrose; D M Grasela
Journal:  Diagn Microbiol Infect Dis       Date:  2000-11       Impact factor: 2.803

4.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

Authors:  H Stass; D Kubitza
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

5.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

Authors:  H M Siefert; A Domdey-Bette; K Henninger; F Hucke; C Kohlsdorfer; H H Stass
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

6.  Development of a murine hypothermia model for study of respiratory tract influenza virus infection.

Authors:  J P Wong; E G Saravolac; J G Clement; L P Nagata
Journal:  Lab Anim Sci       Date:  1997-04

7.  A prediction rule to identify low-risk patients with community-acquired pneumonia.

Authors:  M J Fine; T E Auble; D M Yealy; B H Hanusa; L A Weissfeld; D E Singer; C M Coley; T J Marrie; W N Kapoor
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

8.  Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection.

Authors:  Alison R Kerr; June J Irvine; Jennifer J Search; Neill A Gingles; Aras Kadioglu; Peter W Andrew; William L McPheat; Charles G Booth; Tim J Mitchell
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

9.  In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.

Authors:  E Azoulay-Dupuis; E Vallee; B Veber; J P Bedos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

Authors:  W A Craig; J Redington; S C Ebert
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

View more
  21 in total

1.  Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo.

Authors:  Laura R Marks; G Iyer Parameswaran; Anders P Hakansson
Journal:  Infect Immun       Date:  2012-05-29       Impact factor: 3.441

2.  Severe bacteremia results in a loss of hepatic bacterial clearance.

Authors:  Alix Ashare; Martha M Monick; Linda S Powers; Timur Yarovinsky; Gary W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2006-01-06       Impact factor: 21.405

3.  Host Nitric Oxide Disrupts Microbial Cell-to-Cell Communication to Inhibit Staphylococcal Virulence.

Authors:  Rodolfo Urbano; Joyce E Karlinsey; Stephen J Libby; Paschalis-Thomas Doulias; Harry Ischiropoulos; Helen I Warheit-Niemi; Denny H Liggitt; Alexander R Horswill; Ferric C Fang
Journal:  Cell Host Microbe       Date:  2018-05-09       Impact factor: 21.023

4.  Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.

Authors:  Martina Ulrich; Cordula Albers; Jan-Georg Möller; Axel Dalhoff; Gisela Korfmann; Frank Künkele; Gerd Döring
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.

Authors:  Jamese J Hilliard; John L Melton; LeRoy Hall; Darren Abbanat; Jeffrey Fernandez; Christine K Ward; Rachel A Bunting; A Barron; A Simon Lynch; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Authors:  Calvin C Daniels; Patricia Coan; Janice King; Joanetha Hale; Kimberly A Benton; David E Briles; Susan K Hollingshead
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

7.  Modeling mucosal candidiasis in larval zebrafish by swimbladder injection.

Authors:  Remi L Gratacap; Audrey C Bergeron; Robert T Wheeler
Journal:  J Vis Exp       Date:  2014-11-27       Impact factor: 1.355

8.  Identifying and Implementing Endpoints for Geriatric Mice.

Authors:  Linda A Toth
Journal:  Comp Med       Date:  2018-11-28       Impact factor: 0.982

9.  Streptococcus pyogenes biofilm growth in vitro and in vivo and its role in colonization, virulence, and genetic exchange.

Authors:  Laura R Marks; Lauren Mashburn-Warren; Michael J Federle; Anders P Hakansson
Journal:  J Infect Dis       Date:  2014-01-23       Impact factor: 5.226

10.  Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance.

Authors:  Alix Ashare; Amanda B Nymon; Kevin C Doerschug; John M Morrison; Martha M Monick; Gary W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2008-04-24       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.